- 专利标题： Locked nucleic acid cyclic dinucleotide compounds and uses thereof
-
申请号： US16315612申请日： 2017-07-01
-
公开(公告)号： US11098077B2公开(公告)日： 2021-08-24
- 发明人: David Braun Kanne , Chudi Obioma Ndubaku , Jacob Robert Bruml , Thanh Ngoc Lan Le , Jeffrey McKenna , George Scott Tria , Stephen Canham
- 申请人： CHINOOK THERAPEUTICS, INC. , NOVARTIS AG
- 申请人地址： US WA Seattle; CH Basel
- 专利权人： CHINOOK THERAPEUTICS, INC.,NOVARTIS AG
- 当前专利权人： CHINOOK THERAPEUTICS, INC.,NOVARTIS AG
- 当前专利权人地址： US WA Seattle; CH Basel
- 代理机构： Acuity Law Group, PC
- 代理商 Michael A. Whittaker
- 国际申请： PCT/US2017/040535 WO 20170701
- 国际公布： WO2018/009466 WO 20180111
- 主分类号： C07H21/00
- IPC分类号： C07H21/00 ; A61K45/06 ; A61P35/00 ; A61P17/06 ; A61P31/00 ; A61P37/06 ; A61P3/10 ; A61P1/00 ; A61K9/00 ; C12N15/113
摘要：
The present invention provides highly active locked nucleic acid cyclic-dinucleotide (LNA-CDN) immune stimulators that activate DCs via the cytoplasmic receptor known as STING (Stimulator of Interferon Genes). In particular, the LNA-CDNs of the present invention are provided in the form of a composition comprising one or more cyclic dinucleotides that induce human STING-dependent type I interferon production, wherein the cyclic dinucleotides present in the composition have at least one 2′, 4′ locked nucleic acids within the cyclic dinucleotide.
公开/授权文献
信息查询
